Journals / MN Kardiyoloji / 2012 / Cilt: 19 - Sayı: 2

Update for the management of heart failure: "What says new ESC guidelines?"

Kalp yetersizliği tedavisinde güncelleme: "Yeni ESC kılavuzu ne diyor?"

Pages
100–111
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This is a review of the new guidelines on heart failure with the aim of assisting physicians in selecting the best new management strategies for an individual patient.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Heart failure is a major and growing public health problem in the world.
📊
Key Findings & Data:It is primarily a condition of the elderly, and thus the widely recognized “aging of the population” also contributes to the increasing incidence of heart failure.
💡
Conclusion & Impact:This is a review of the new guidelines on heart failure with the aim of assisting physicians in selecting the best new management strategies for an individual patient.
🔬Design:Review & Systematic Survey
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Heart failure is a major and growing public health problem in the world. It is primarily a condition of the elderly, and thus the widely recognized “aging of the population” also contributes to the increasing incidence of heart failure. The number of heart failure deaths has increased steadily despite advances in treatment, in part because of increasing numbers of patients with heart failure due to bet- ter treatment and “salvage” of patients with acute myocardial infarctions earlier in life.A large number of guidelines have been is- sued by the European Society of Cardiology as well as by other societies for the best management strategies for heart failure patient. The European Society of Cardiology published revised guidelines for the evaluation and management of acute and chronic heart fail- ure in May, 2012. This is a review of the new guidelines on heart failure with the aim of assisting physicians in selecting the best new management strategies for an individual patient.

Özet

Kalp yetersizliği tüm dünyada sıklığı giderek artan en önemli sağlık sorunlarından birisidir. Yaşlanma ile birlikte insidansı arttığı için, toplumun giderek yaşlandığı da göz önüne alırsak, kalp yetersizliği genel olarak yaşlıların bir hastalığı olarak kabul edilmektedir. Tedavi yaklaşımlarındaki gelişmelere rağmen kalp yetersizliğine bağlı ölümler artmaktadır. Bu artıştan akut miyokard enfarktüsü son- rası hayatta kalan ve kalp yetersizliği gelişen hasta sayısındaki artış da sorumludur. Avrupa Kardiyoloji Derneği ve diğer başka birçok dernek tarafından kalp yetersizliği hastalarına en iyi tedaviyi uygulayabilmek için kılavuzlar yayınlanmıştır. Avrupa Kardiyoloji Derneği Mayıs 2012'de Akut ve Kronik Kalp Yetersizliği Tanı ve Tedavi Kılavuzu’nu yenilemiştir. Kalp yetersizliği kılavuzunun bu derlemesi ile he- kimlere hastalarına en yeni tedavi yaklaşımlarını uygulamada yardımcı olmayı amaçladık.

🔖

Cite This Article

TEMİZHAN, A., KORKMAZ, A. (2012). Update for the management of heart failure: "What says new ESC guidelines?". MN Kardiyoloji, Cilt: 19 - Sayı: 2, 100–111. https://ajindex.com/articles/297438

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787- 1847
  2. Pitt B, Zannad F, Remme WJ, et al. The effect of spirono- lactone on morbidity and mortality in patients with se- vere heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717
  3. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21
  4. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dys- function after myocardial infarction. N Engl J Med 2003; 348:1309-1321
  5. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885
  6. The effect of digoxin on mortality and morbidity in patients with heart failure.The Digitalis Investigation Group. N Engl J Med 1997;336:525-533
  7. Hood WB Jr, Dans AL, Guyatt GH, Jaeschke R, McMurray JJ. Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta- analysis. J Card Fail 2004;10:155-164
  8. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico-heart failure) çalışmasıdır (Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, doubleblind, placebo-controlled trial. Lancet 2008;372:1223-1230
  9. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchro- nization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-1338
  10. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchro- nization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385-2395
  11. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery by- pass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364:1607-1616
  12. Jones RH, Velazquez EJ, Michler RE, et al. Coronary by- pass surgery with or without surgical ventricular recon- struction. N Engl J Med 2009;360:1705-1717
  13. Smith CR, Leon MB, Mack MJ, et al. for the PARTNER Trial Investigators. Tran